Leading Urea Cycle Disorders Companies | Major Players 2026

Code: MTA14399 Publication Date: Oct 2026

Leading Urea Cycle Disorders Companies

The following is a data-backed list of the leading Urea Cycle Disorders companies, compiled through 6Wresearch's proprietary research and validated by in-house industry analysts. Abbott Laboratories, Takeda Pharmaceutical Company currently lead the competitive landscape, alongside several other established players shaping the Global Urea Cycle Disorders Market.

For detailed forecasts, data tables, and competitive benchmarking,
Explore the full Global Urea Cycle Disorders Market.

List of Urea Cycle Disorders Companies:

1. Abbott Laboratories

Company NameAbbott Laboratories
Established Year1888
HeadquartersAbbott Park, Illinois, United States
Official WebsiteClick Here

Abbott Laboratories is a global healthcare giant manufacturing specialized medical nutrition products, therapeutic formulas, and metabolic diets designed for infants and children diagnosed with inborn errors of metabolism such as PKU and MSUD.

2. Takeda Pharmaceutical Company Limited

Company NameTakeda Pharmaceutical Company Limited
Established Year1781
HeadquartersTokyo, Japan
Official WebsiteClick Here

Takeda Pharmaceutical Company is a biopharmaceutical pioneer specializing in rare disease therapies, delivering enzyme replacement treatments and innovative biologics for lysosomal storage disorders and hereditary metabolic conditions.

3. Spyre Therapeutics, Inc.

Company NameSpyre Therapeutics, Inc.
Established Year2013
HeadquartersWaltham, Massachusetts, United States
Official WebsiteClick Here

Spyre Therapeutics is a biotechnology enterprise focused on developing novel biological therapies and engineered human enzymes to address rare metabolic diseases and inflammatory conditions.

4. B. Braun Melsungen AG

Company NameB. Braun Melsungen AG
Established Year1839
HeadquartersMelsungen, Germany
Official WebsiteClick Here

B. Braun Melsungen AG is an international healthcare manufacturer offering specialized clinical nutrition systems, amino acid solutions, and parenteral infusion products essential for managing patients with severe metabolic imbalances.

5. Orpharma Pty Ltd.

Company NameOrpharma Pty Ltd.
Established Year2011
HeadquartersMelbourne, Victoria, Australia
Official WebsiteClick Here

Orpharma Pty Ltd. is a specialized pharmaceutical company focused on the acquisition, development, and commercialization of orphan drugs and medical nutrition products for patients suffering from rare genetic and metabolic disorders.

6. Pfizer Inc.

Company NamePfizer Inc.
Established Year1849
HeadquartersNew York City, New York, United States
Official WebsiteClick Here

Pfizer Inc. is a leading biopharmaceutical corporation with a dedicated rare disease division, developing targeted gene therapies, small molecule therapeutics, and endocrinology solutions for rare metabolic and genetic conditions.

7. Arcturus Therapeutics Holdings Inc.

Company NameArcturus Therapeutics Holdings Inc.
Established Year2013
HeadquartersSan Diego, California, United States
Official WebsiteClick Here

Arcturus Therapeutics is a messenger RNA (mRNA) medicine company developing targeted therapeutics and vaccines, utilizing proprietary LUNAR lipid-mediated delivery systems to treat rare metabolic disorders like OTC deficiency.

8. Cambrooke Therapeutics

Company NameCambrooke Therapeutics
Established Year2000
HeadquartersAyer, Massachusetts, United States
Official WebsiteClick Here

Cambrooke Therapeutics is a medical nutrition developer producing specialized low-protein foods, amino acid formulas, and dietary management solutions for individuals living with PKU, tyrosinemia, and other metabolic diseases.

9. Acer Therapeutics Inc. (Part of Zevra Therapeutics)

Company NameAcer Therapeutics Inc. (Part of Zevra Therapeutics)
Established Year2013
HeadquartersNewton, Massachusetts, United States
Official WebsiteClick Here

Acer Therapeutics (acquired by Zevra Therapeutics) is a pharmaceutical firm focused on developing and commercializing therapies for rare, life-threatening metabolic diseases, including urea cycle disorders (UCDs).

10. Horizon Therapeutics plc (A Subsidiary of Amgen)

Company NameHorizon Therapeutics plc (A Subsidiary of Amgen)
Established Year2008
HeadquartersDublin, Ireland
Official WebsiteClick Here

Horizon Therapeutics is a biopharmaceutical leader specializing in rare, autoimmune, and severe inflammatory diseases, offering targeted enzyme therapies to manage chronic refractory gout and rare metabolic conditions.

Frequently Asked Questions About the Market Study (FAQs):
6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.
Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com
ISO 9001:2015

ISO 9001:2015 CERTIFIED

Quality Management System for market research & advisory services

Cert. No. 3050261008135Q

6Wresearch Support

Any Query

Call: +91-11-4302-4305
Email us: sales@6wresearch.com
Any Query? Click Here

Thought Leadership and Analyst Meet

Our Clients

Airtel
Canon
Contec
HoneyWell
Kriloskar
Pwc Logo
Samsung
Tata Teleservices

Whitepaper

Read All